Emerging retatrutide, a combined-action drug targeting simultaneously GLP-1 and GIP receptors, is creating considerable excitement within the healthcare community. Early clinical research have revealed significant decreases in overall weight and gains in health markers for individuals with obesity . Scientists believe this unique approach could mar